Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company whose news flow reflects its dual focus on royalty-based income and commercial-stage infectious disease and critical care therapies. Company announcements frequently highlight performance of its royalties portfolio tied to GSK respiratory products RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, alongside updates from Innoviva Specialty Therapeutics (IST), its critical care and infectious disease platform.
News releases from Innoviva and IST cover quarterly financial results, including royalty revenue and net product sales, as well as regulatory milestones and product launches. Examples include FDA acceptance and Priority Review of the New Drug Application for zoliflodacin, subsequent FDA approval of NUZOLVENCE® (zoliflodacin) for uncomplicated urogenital gonorrhea, and the U.S. launch of ZEVTERA® (ceftobiprole) for serious bacterial infections such as Staphylococcus aureus bloodstream infections, ABSSSI, and CABP.
Investors and healthcare professionals can also find coverage of clinical and scientific data presentations at major conferences like IDWeek, where Innoviva Specialty Therapeutics presents Phase 3 results, subgroup analyses, pharmacokinetic-pharmacodynamic studies, and microbiologic surveillance for agents including zoliflodacin, ZEVTERA, XACDURO®, and XERAVA®. Additional news items describe capital allocation decisions, such as share repurchase authorizations, strategic investments in healthcare companies, and licensing or acquisition of new platforms and assets.
This INVA news page aggregates these updates in one place, making it easier to track earnings announcements, regulatory decisions, conference presentations, and portfolio developments. Readers interested in Innoviva’s evolving role in respiratory royalties, antibiotic development, and critical care therapeutics can use this feed to monitor key events and company disclosures over time.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a leading critical care and infectious disease platform, announced its participation in the Citi 2024 Global Healthcare Conference. CEO Pavel Raifeld will join a fireside chat on December 5, 2024, at 8:45 a.m. Eastern Time in Miami, FL. A live webcast of the chat will be available under the 'Events & Presentations' section on Innoviva's website. The webcast will remain accessible for replay for 90 days.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a critical care and infectious disease platform, announced its management's participation in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA.
The event will take place on Wednesday, November 13, 2024, at 10:15 a.m. Pacific Time. A live webcast can be accessed under the 'Events & Presentations' section of Innoviva's Investor Relations website. The webcast will be available for replay for 90 days after the event.
Innoviva reported third quarter 2024 financial results, highlighting strong performance and significant progress. Key points include:
Royalty revenue: $60.5 million from GSK, a 6% year-over-year increase.
Net product sales: $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% growth. GIAPREZA® contributed $13.1 million, XERAVA® $2.3 million, and XACDURO® $4.3 million.
License revenue: $4.6 million from development cost-sharing reimbursements.
Net income: $1.2 million, or $0.02 per share, down from $82.0 million, or $1.26 per share in Q3 2023.
Cash and assets: $260.6 million in cash and equivalents, with $91.1 million in receivables.
Notable achievements include the nomination of XACDURO® for the 2024 Prix Galien USA Award and plans to submit an NDA for zoliflodacin in early 2025.
Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 10:30 a.m. Eastern Time. Additionally, Innoviva will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, at 3:40 p.m. Eastern Time.
Both presentations will be accessible via live webcasts in the Investor Relations section of Innoviva's website. Archived replays will also be available after the events. This participation demonstrates Innoviva's commitment to engaging with investors and showcasing its portfolio, which includes a core royalties segment and a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST).
Innoviva (NASDAQ: INVA) reported strong Q2 2024 financial results, showcasing growth across multiple fronts. Key highlights include:
- GSK royalties of $67.2 million, up from $65.7 million in Q2 2023
- Net product sales of $21.7 million, a 38% year-over-year increase
- License revenue of $14.5 million, including an $8 million milestone payment for XACDURO® approval in China
- Net loss of $34.7 million, primarily due to unfavorable changes in investment fair values
- Completed $100 million share repurchase program
The company's core products, XACDURO® and XERAVA®, received recognition in important treatment guidelines. Innoviva remains focused on enhancing shareholder value through capital allocation and operational excellence.
Innoviva (Nasdaq: INVA), a diversified holding company with a core royalties portfolio and a strong presence in critical care and infectious disease through Innoviva Specialty Therapeutics (IST), announced that its CEO, Pavel Raifeld, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL on June 10, 2024, at 1:20 p.m. Eastern Time. The session will be available via live webcast on the company's Investor Relations webpage and can be replayed for 90 days.
Innoviva, Inc. (NASDAQ: INVA) reported strong first quarter financial results with $61.9 million in GSK royalties, $19.1 million in net product revenues, and a successful pipeline. The company highlighted positive Phase 3 zoliflodacin clinical trial results and key appointments.
Innoviva, Inc. (NASDAQ: INVA) will participate in the BofA Securities Health Care Conference. The company, a holding firm with a core royalties portfolio and a strong presence in critical care and infectious disease treatment, will have its CEO, Pavel Raifeld, present at the conference on May 15, 2024. Interested parties can access a live webcast of the event on the company's Investor Relations website.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Innoviva (INVA)?
What is the market cap of Innoviva (INVA)?
